oncology
Risk factors

Simple risk tool predicts immunotherapy response in melanoma patients


With no molecular biomarkers to predict immunotherapy response in metastatic melanoma, Sydney researchers have found that a combination of standard clinical measures such as baseline blood parameters help predict overall survival. In what they say could be a simple and useful tool for clinical decision making, researchers at the  Melanoma Institute Australia, University of Sydney ...

Already a member?

Enter your email to keep reading.


OR